Fall 2026
Posted on 7/21/2026
Bioprints allogeneic tissue therapeutics
CA$21.63 - CA$23.08/hr
Vancouver, BC, Canada
In Person
Find people who can refer or advise you
Aspect Biosystems develops bioprinted tissue therapeutics for regenerative medicine. Its work centers on a platform that combines proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create allogeneic tissue therapeutics for clinical use. The company works through strategic collaborations with leading pharmaceutical and biotechnology firms, funded by partnerships and investors. The product approach uses bioprinting to assemble tissue constructs layer by layer from cells and biomaterials, guided by computational design, producing off-the-shelf (allogeneic) tissue therapies. What sets the company apart is its integrated platform, a focus on allogeneic, scalable tissue products, and a collaboration-driven business model with strong industry partnerships, backed by a solid funding base. Its goal is to advance regenerative medicine by delivering a targeted pipeline of bioprinted tissue therapeutics through collaborations and continued investment.
Company Size
51-200
Company Stage
N/A
Total Funding
$294.8M
Headquarters
Vancouver, Canada
Founded
2013
Find people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Company Equity
Canadian government supports SFU VentureLabs Alumni, Aspect Biosystems with $79 Million in funding. On April 2nd, the Government of Canada announced an investment of $79 Million for SFU VentureLabs Alumni, Aspect Biosystems. This initiative was conducted through the Strategic Response Fund (SRF), a fund focused on supporting Canadian industries' innovation, adaptation and competition in an evolving global economy. The Province of British Columbia will also be supporting Aspect Biosystems with $23.8 million to expand the company. The national government is strengthening its partnership with Aspect Biosystems with an additional $280 million collaboration that supports the scaling of Aspect's clinical development, enhances their AI-platform and accelerates the commercialization process. This installation will create upwards of 400 jobs for employees and co-op students alike. Aspect Biosystems' CEO, Tamer Mohammed remains enthusiastic about this joint effort. "With this investment and the deepening of our partnership with the Government of Canada, we are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world.", said Mohammed Tamer, CEO of Aspect Biosystems
InBC has invested in Vancouver-based Aspect Biosystems, a biotech firm developing bioprinted tissue therapeutics for diseases like diabetes and obesity. The company partners with Novo Nordisk to create treatments for type 1 diabetes. This investment supports Aspect's expansion and aligns with B.C.'s strategy to become a life sciences hub. Aspect previously received funding from Canadian and B.C. governments to enhance its biomanufacturing capabilities.